Paracentesis-induced circulatory dysfunction: are there albumin alternatives?

被引:6
作者
Alsebaey, Ayman [1 ]
Rewisha, Eman [1 ]
Waked, Imam [1 ]
机构
[1] Menoufia Univ, Natl Liver Inst, Dept Hepatol & Gastroenterol, Shibin Al Kawm 32511, Egypt
关键词
Ascites; Large volume paracentesis; Albumin; Paracentesis-induced circulatory dysfunction; LARGE-VOLUME PARACENTESIS; REFRACTORY ASCITES; CIRRHOTIC-PATIENTS; TENSE ASCITES; HEPATORENAL-SYNDROME; LIVER-CIRRHOSIS; ADULT PATIENTS; FLOW-RATE; MANAGEMENT; PREVENTION;
D O I
10.1186/s43066-020-00047-7
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Ascites is one of the main complications of advanced liver cirrhosis. It is defined as a pathological accumulation if free fluid in the peritoneal cavity. Main body of the abstract Ascites is a sign of decompensation in patients with liver cirrhosis and is associated with decreased survival. Ascites is associated with bad cosmetic figure and poor quality of life. Ascites is a predisposing factor for developing hydrothorax, hernias, diastolic dysfunction, spontaneous bacterial peritonitis, and renal impairment especially hepatorenal syndrome. The main treatment is salt restriction and diuretics. By the time the patient become non-responder and develop tense ascites, abdominal large volume paracentesis is the treatment of choice. Its advantages are rapid, cheap, and 1 day hospitalization. The main drawback is the development of paracentesis-induced circulatory dysfunction (PICD) if no volume expanding drugs are used. PICD is associated with dilutional hyponatremia, renal impairment, so it is considered the silent killer. Albumin infusion is the standard preventive measure but since costly to other alternatives such as colloids, vasoconstrictors or lowering the standard doses of the albumin was studied and is promising. Conclusions This review summarized the effectiveness of other alternative drugs.
引用
收藏
页数:6
相关论文
共 60 条
  • [1] Abdel-Khalek E.E., 2010, Arab J. Gastroenterol, V11, P24, DOI DOI 10.1016/J.AJG.2010.01.006
  • [2] HISTORICAL HEPATOLOGY - BEETHOVEN,LUDWIG,VON
    ADAMS, PC
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1987, 2 (04) : 375 - 379
  • [3] Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: Standard vs half albumin doses. A prospective, randomized, unblinded pilot study
    Alessandria, Carlo
    Elia, Chiara
    Mezzabotta, Lavinia
    Risso, Alessandro
    Andrealli, Alida
    Spandre, Maurizio
    Morgando, Anna
    Marzano, Alfredo
    Rizzetto, Mario
    [J]. DIGESTIVE AND LIVER DISEASE, 2011, 43 (11) : 881 - 886
  • [4] Alsebaey A, 2013, EGYPT LIVER J, V3, P118
  • [5] Alsebaey A, 2020, Egypt Liver J, V10, P1
  • [6] Prevention of paracentesis-induced circulatory dysfunction:: midodrine vs albumin.: A randomized pilot study
    Appenrodt, Beate
    Wolf, Andrea
    Gruenhage, Frank
    Trebicka, Jonel
    Schepke, Michael
    Rabe, Christian
    Lammert, Frank
    Sauerbruch, Tilman
    Heller, J.
    [J]. LIVER INTERNATIONAL, 2008, 28 (07) : 1019 - 1025
  • [7] Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis
    Arroyo, V
    Gines, P
    Gerbes, AL
    Dudley, FJ
    Gentilini, P
    Laffi, G
    Reynolds, TB
    RingLarsen, H
    Scholmerich, J
    [J]. HEPATOLOGY, 1996, 23 (01) : 164 - 176
  • [8] Albumin infusion in patients undergoing large-volume paracentesis: A meta-analysis of randomized trials
    Bernardi, Mauro
    Caraceni, Paolo
    Navickis, Roberta J.
    Wilkes, Mahlon M.
    [J]. HEPATOLOGY, 2012, 55 (04) : 1172 - 1181
  • [9] Transjugular intrahepatic portosystemic shunt: Current status
    Boyer, TD
    [J]. GASTROENTEROLOGY, 2003, 124 (06) : 1700 - 1710
  • [10] Bryan CP, 1931, PAPYRUS EBERS, P134